Tirzepatide
Dual GLP-1 / GIP agonist
Tirzepatide is a dual agonist that interacts with 2 receptors, specifically targeting both the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide pathways.
It is frequently viewed as an evolved version of semaglutide that allows for higher overall dosing, even though it is considered less effective per milligram on the GLP-1 receptor alone.
The compound is noted for its ability to transform eating habits by neutralizing dopamine reward pathways associated with sugar. Many users find it more effective than other agents for curbing cravings and maintaining weight loss after hitting a plateau on single agonist medications.
Tirzepatide has a half life of 5 days, dosing protocols typically start at 2 mg weekly for maintenance and can titrate up to 6 mg or 10 mg during intensive cutting phases. Injections are typically done once a week, or split into 2.
Common side effects include constipation and mild digestive symptoms.